CVS names David Joyner new CEO, replacing Karen Lynch

Published On Oct 18, 2024, 8:20 AM

CVS Health has appointed David Joyner as its new CEO, succeeding Karen Lynch, who stepped down from her position. Joyner has a long history in healthcare and pharmacy management, previously serving as the president of CVS Caremark. The leadership change comes during a challenging time for CVS, as the company has recently adjusted its earnings outlook downward and announced plans to cut operational costs and store closures in response to rising medical costs and competitive pressures.

Read full article

Stock Forecasts

CVSView CVS chart on TradingView

Negative

The leadership change typically brings a wave of uncertainty but can also present opportunities for revitalization and strategic redirection. Given Joyner's previous experience, there are potential upsides if he implements effective turnaround strategies. However, the immediate challenges such as rising medical costs and a need for cost-cutting measures may lead to a cautious outlook.

Related News

CVS replaces CEO, pulls profit forecast as investor pressure mounts

Oct 18, 2024, 8:22 AM

Shares fell 11% in premarket trading, adding to this year's losses, as CVS also forecast quarterly adjusted profit below estimates. Shareholders have become increasingly nervous about repeated profit forecast cuts this year as its drugstores face reimbursement pressures and high costs hit the health insurance industry. Investor Glenview Capital said earlier this month it was working with CVS to help improve operations as the company faces one of the most challenging periods in its six-decade history.

CVS

Why neighborhood pharmacies are closing

Oct 18, 2024, 6:00 AM

Retail pharmacies will never be obsolete, according to an analyst. But the industry needs to take a hard look at how many stores are needed and what items they should sell.

CVS
WBA

'Barron's Roundtable' gives CVS outlook amid calls of a breakup | Fox Business Video

'Barron's Roundtable' panelists discuss calls of a breakup for CVS prompting a strategic review.

CVS